Concomitant with the release of human immunodeficiency virus type 1 (HIV-1) particles from the infected cell, the viral protease cleaves the Gag polyprotein precursor at a number of sites to trigger virus maturation. We previously reported that a betulinic acid-derived compound, bevirimat (BVM), blocks HIV-1 maturation by disrupting a late step in protease-mediated Gag processing: the cleavage of the capsid-spacer peptide 1 (CA-SP1) intermediate to mature CA. BVM was shown in multiple clinical trials to be safe and effective in reducing viral loads in HIV-1-infected patients. However, naturally occurring polymorphisms in the SP1 region of Gag (e.g., SP1-V7A) led to a variable response in some BVM-treated patients. The reduced susceptibility of SP1-polymorphic HIV-1 to BVM resulted in the discontinuation of its clinical development. To overcome the loss of BVM activity induced by polymorphisms in SP1, we carried out an extensive medicinal chemistry campaign to develop novel maturation inhibitors. In this study, we focused on alkyl amine derivatives modified at the C-28 position of the BVM scaffold. We identified a set of derivatives that are markedly more potent than BVM against an HIV-1 clade B clone (NL4-3) and show robust antiviral activity against a variant of NL4-3 containing the V7A polymorphism in SP1. One of the most potent of these compounds also strongly inhibited a multiclade panel of primary HIV-1 isolates. These data demonstrate that C-28 alkyl amine derivatives of BVM can, to a large extent, overcome the loss of susceptibility imposed by polymorphisms in SP1.
H
uman immunodeficiency virus type 1 (HIV-1), the primary causative agent of AIDS, is currently estimated to infect Ͼ33 million people worldwide (http://www.healthline.com/health/hiv -aids/facts-statistics-infographic). A number of inhibitors have been developed that suppress HIV-1 replication in infected patients, and there are currently more than two dozen anti-HIV-1 drugs approved for clinical use (1) . These inhibitors, which are administered in combination (combination antiretroviral therapy [cART] ), fall into several major classes. Inhibitors of the viral enzymes reverse transcriptase (RT), protease (PR), and integrase (IN) form the backbone of current cART regimens. Inhibitors that target fusion and entry are also available (1) .
Although current cART is able to suppress viral loads to below the level of detection of standard commercial assays in the majority of treatment-compliant individuals, available therapies are not curative and thus require lifelong drug adherence. Long-term treatment is associated with a variety of issues related to drug toxicity, unfavorable drug-drug interactions, and patient noncompliance. Multidrug resistance is likely to limit treatment options in an increasing number of patients over time, particularly in resource-limited settings, where viral load testing is not widely available (2) (3) (4) (5) . Thus, it is imperative that continued efforts be made to develop novel drugs targeting steps in the viral replication cycle not affected by current therapies. As an added benefit, developing inhibitors against novel targets provides a wealth of basic mechanistic information about fundamental aspects of viral replication.
Maturation of HIV-1 particles, which is triggered by the action of the viral PR, occurs concomitantly with virion release from the infected cell (6) (7) (8) . PR cleaves a number of sites in the Gag polyprotein precursor, Pr55
Gag , the major structural protein responsible for the formation of virus particles. PR-mediated Gag cleavage gives rise to the matrix (MA), capsid (CA), nucleocapsid (NC), and p6 proteins and to two small spacer peptides, SP1 and SP2, located between CA and NC and between NC and p6, respectively. PR also cleaves the Gag-Pol polyprotein precursor to generate the mature viral enzymes, i.e., PR, RT, and IN. Cleavage of the Gag and Gag-Pol polyproteins results in a marked change in virion morphology. In the immature particle, the Gag precursor proteins are arranged radially around the outer edge of the virus particle, whereas in the mature virion the CA proteins assemble into a centrally located, conical core (referred to as the capsid) in which the viral RNA genome and the viral enzymes RT and IN reside.
Both Pr55
Gag and mature CA assemble into a largely hexameric lattice, though the unit-to-unit spacing of the lattice and the intersubunit contacts differ between the immature and mature lattices (9) . The strain of curvature is accommodated in the immature Gag lattice by the presence of gaps, whereas in the mature capsid the inclusion of a total of 12 pentamers in the otherwise hexameric capsid lattice allows the capsid to close off at both ends (10) (11) (12) . Maturation is critical to particle infectivity (7).
Each processing site within the Gag and Gag-Pol polyprotein precursors is cleaved by PR with distinct kinetics, largely due to the unique primary amino acid sequence at each site (13) (14) (15) (16) (17) (18) (19) . The consequence of the differential rates of cleavage is that Gag and Gag-Pol processing occurs as a highly ordered cascade of cleavage events. This highly ordered processing is required for proper maturation. Defects in maturation can affect both virus entry (20, 21) and subsequent postentry events. Even partial disruption of processing at several sites in Gag leads to severely impaired virus infectivity (22) (23) (24) , highlighting the utility of Gag processing as a target for antiretrovirals.
We and others previously reported that the first-in-class HIV-1 maturation inhibitor 3-O-(3=-3=-dimethylsuccinyl) betulinic acid (bevirimat [BVM]) (25) acts by blocking cleavage at the CA-SP1 junction (26, 27) . We selected a panel of resistant mutants by propagating HIV-1 in the presence of BVM; the resistance mutations mapped to the CA-SP1 boundary region (28) . Clinical trials showed that BVM was safe and efficacious. However, polymorphisms present in circulating strains of HIV-1 diminished the efficacy of BVM. These polymorphisms cluster in a Gln-Val-Thr (QVT) sequence spanning SP1 residues 6 to 8. In particular, we observed that, in culture, a Val-to-Ala change at SP1 residue 7 (V7A) almost completely abrogated the ability of BVM to block CA-SP1 processing and virus replication (29) . Our analysis of the structurally distinct maturation inhibitor PF-46396 (30) demonstrated that this compound retained activity against a derivative of clade B NL4-3 bearing the V7A change (31) . This result, together with recent reports describing chemically modified BVM derivatives (32) (33) (34) , suggested that the insensitivity of SP1-polymorphic HIV-1 to maturation inhibitors could be overcome.
In this study, we synthesized a collection of novel C-28 alkyl amine derivatives of BVM and tested their ability to block CA-SP1 processing and virus replication by using wild-type (WT) NL4-3 and a V7A variant of NL4-3 that is resistant to BVM. The activities of these compounds against a multiclade panel of HIV-1 isolates were also determined. The results demonstrated that several of these derivatives were markedly more potent and more broadly active than the parental BVM compound, with low-nanomolar antiviral activity against both WT NL4-3 and the V7A derivative.
MATERIALS AND METHODS
Chemical synthesis. Scaffold 7 compounds (Table 1) were synthesized by modification of C-3 and C-28 of betulin. Oxidation of C-28 allowed acylation followed by deprotection at C-3 to provide the left-hand side of the molecule. Further homologation following by oxidation and reductive animation at C-28 furnished the right-hand side of the molecule, resulting in compounds 7a to 7t (Table 1) . See the supplemental material for additional details.
Cell culture, plasmids, and transfections. The MT-4 T-cell line was maintained in RPMI 1640 medium supplemented with 10% (vol/vol) fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin at 37°C in a humidified 5% CO 2 atmosphere. HeLa and 293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (vol/vol) FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. The molecular clones used in this study were WT pNL4-3 (35) and a derivative encoding a Val-to-Ala mutation at SP1 residue 7, referred to as the V7A variant (29) . HeLa and 293T cells were transfected by use of linear polyethylenimine (L-PEI) or Lipofectamine 2000 (Invitrogen) (36, 37) .
CA-SP1 accumulation assay. CA-SP1 accumulation assays were performed as described previously (28, 31, 37) , with some modification. Briefly, HeLa cells were transfected with WT pNL4-3 or the V7A variant.
At 24 h posttransfection, cells were starved in Met/Cys-free medium for 30 min and then metabolically labeled with [ 35 S]Met/Cys-Pro mix (PerkinElmer) for 2 to 3 h. Maturation inhibitors were maintained in the cultures throughout the transfection and labeling period. Viruses were collected by ultracentrifugation at 75,000 ϫ g for 45 to 60 min. Virus pellets were resuspended in Triton X-100 lysis buffer (300 mM NaCl, 50 mM Tris-HCl [pH 7.5], 0.5% Triton X-100, 10 mM iodoacetamide, and protease inhibitor cocktail tablets [Roche] ). CA and CA-SP1 proteins were separated in gels containing between 13.5 and 15% polyacrylamide by SDS-polyacrylamide gel electrophoresis, exposed to a phosphorimager plate (Fuji), and quantified by use of Quantity One software (Bio-Rad).
Antiviral assays. To produce HIV-1 stocks, 293T cells were transfected with WT pNL4-3 or the V7A variant, and culture supernatants were collected at 24 h posttransfection. RT-normalized virus supernatants were used to infect MT-4 cells at room temperature for 30 min. Cells were then cultured in the presence of serial dilutions of each compound. At 4 days postinfection, the culture supernatants were subjected to RT assay to monitor viral replication as previously described (37) . The 50% inhibitory concentrations (IC 50 s) were defined as compound concentrations that reduced RT levels to 50% of those measured in the absence of inhibitor (dimethyl sulfoxide [DMSO]-only controls) and were determined using GraphPad Prism 6 software (38) . The IC 50 s in primary peripheral blood mononuclear cells (PBMCs) were determined by Southern Research Institute (Frederick, MD) for a multiclade panel of HIV-1 isolates, as reported previously (38) . PBMCs were purified from anonymized, healthy blood donors by Ficoll-Hypaque gradient centrifugation. Cells were stimulated for 3 days with phytohemagglutinin and interleukin-2 prior to infection with HIV-1. IC 50 s were calculated as described above, based on reductions in RT activity on day 6 postinfection.
Cytotoxicity assays. Cytotoxicity was measured with the CellTiterBlue cell viability assay according to the manufacturer's protocol (Promega). Two cell lines, MT-4 and HeLa, were used in this assay. Cells were incubated with serial dilutions of compounds at 37°C for 4 or 8 days and then treated with CellTiter-Blue reagent. The fluorescence signal was measured at 560 nm (excitation)/590 nm (emission) by use of a plate reader (Infinite M1000 Pro; Tecan). The 50% cytotoxic concentrations (CC 50 s) were defined as compound concentrations at which the fluorescence signals were reduced by 50% relative to that of the no-inhibitor (DMSO only) controls and were determined using GraphPad Prism 6 software. Cytotoxicity in PBMCs was determined as described previously (38) .
RESULTS
C-28 BVM analogs inhibit CA-SP1 processing of both WT HIV-1 strain NL4-3 and the SP1-V7A derivative. Previous results from this laboratory indicated that compounds containing scaffold 7 possessed some activity against V7A variants (data not shown). To identify BVM analogs with an increased potency and breadth of activity, we synthesized a panel of related C-28-homologated amines (Table 1 ; see Materials and Methods and the supplemental information). We then tested the ability of these derivatives to inhibit CA-SP1 processing of a clade B viral clone, NL4-3, and the BVM-resistant V7A variant (29) . HeLa cells transfected with pNL4-3 or the V7A variant were left untreated or were treated with 100 nM (each) compounds 7a to 7j and then metabolically radiolabeled with [ 35 S]Met/Cys. Released virus particles were concentrated by ultracentrifugation, and lysates were subjected to SDS-PAGE and fluorography (see Materials and Methods). This approach evaluates the ability of a maturation inhibitor to block CA-SP1 processing in a quantitative manner by measuring the percentage of CA-SP1 accumulation. As indicated in Fig.  1A , treatment with BVM or with analogs 7a to 7j led to a marked accumulation (ϳ50 to 80%) of CA-SP1 for WT NL4-3. In contrast, and consistent with our previous report (29) , for samples transfected with the V7A mutant the BVM treatment resulted in only ϳ10% accumulation of CA-SP1, which is comparable to the level for the DMSO control (Fig. 1B) . For the remaining compounds in this set, levels of CA-SP1 accumulation ranged from ϳ15 to 55%, with compounds 7h and 7j, which incorporate an additional amino grouping into the C-28 side chain, showing the greatest potencies in disrupting CA-SP1 processing. Based on these results, we synthesized a new set of compounds (7k to 7t) and evaluated their potency in the CA-SP1 accumulation assay. Compared to BVM, compounds 7k to 7t were considerably more effective against WT NL4-3 (Fig. 1C) and showed a high degree of potency against the V7A mutant (Fig. 1D) , with V7A mutant CA-SP1 accumulation in the 60% range for many of these compounds (Fig. 1D) .
To refine our analysis of CA-SP1 accumulation, we focused on compounds with the lowest IC 50 s against the V7A variant, namely, 7m, 7n, 7r, and 7s, and performed a dose-response analysis. Virusproducing cells were treated with increasing concentrations of compound (0.8 to 100 nM). WT NL4-3 showed a dose-dependent accumulation of CA-SP1 when cells were treated with BVM, while SP1-V7A was resistant to all concentrations used ( Fig. 2A and B) . In contrast, compounds 7m, 7n, 7r, and 7s showed strong doseresponsive accumulations of CA-SP1 for both WT NL4-3 ( Fig.  2A ) and the V7A mutant (Fig. 2B) .
C-28 BVM analogs display low-nanomolar antiviral activity against WT NL4-3 and the SP1-V7A derivative. Our previous studies established a close correlation between the inhibition of CA-SP1 processing imposed by BVM and the compound's antiviral activity (28, 29, 31) . To determine whether this correlation extends to the BVM analogs being studied here, we used a virus replication assay based on spreading HIV-1 infection in the MT-4 T-cell line to measure the IC 50 s of the compounds. HIV-1-infected MT-4 cells were cultured for 4 days in the presence of serial dilutions of each compound. Antiviral activity was monitored by reductions in RT activity in culture supernatants. As shown in Table 2 , the IC 50 s of the first series of compounds against WT NL4-3 were mainly in the range of 10 to 20 nM. Against the V7A variant, compounds 7h and 7j had IC 50 s of 76 and 39 nM, respectively. The significantly improved antiviral activities of 7h and 7j against the V7A variant paralleled the increased ability of these compounds to inhibit CA-SP1 processing relative to that of BVM (Fig. 1B) . Most of the second series of compounds (7k to 7t) displayed single-digit nanomolar IC 50 s against the WT and predominantly sub-20 nM IC 50 s against the V7A variant. Compounds 7m, 7n, 7r, and 7s showed low-nanomolar activities against SP1-V7A (ϳ9, 14, 10, and 8 nM, respectively). As seen with 7s and 7t, additional substitution on the second amine grouping is tolerated and will allow for continued exploration of structure-activity relationships for this series of analogs. We also evaluated the cytotoxicity of these BVM analogs by using the CellTiter-Blue cell viability assay with HeLa and MT-4 cells (see Materials and Methods). As shown in Table 3 , although many of the highly potent compounds displayed increased cytotoxicity in HeLa and MT-4 cells relative to that of BVM, the CC 50 values for all the BVM analogs were considerably higher than the concentrations required for maximal (plateau) antiviral activity.
C-28 BVM analogs are broadly active against multiple clades of HIV-1. Polymorphisms in SP1 (e.g., V7A) reduce the susceptibility of HIV-1 to BVM in both in vitro assays and in vivo, in HIV-1-infected patients. To assess the breadth of antiviral activity displayed by our novel panel of BVM analogs, we extended our analyses to a panel of primary HIV-1 isolates that includes representative viruses from HIV-1 subtypes A, B, C, D, E, F, and G. This panel of isolates was selected in part because of their highly diverse SP1 sequences (Fig. 3) . Compound 7r was selected for this analysis because of its high level of potency against the V7A variant. Antiviral activity in PBMCs was measured by quantifying the reduction in RT activity in the culture supernatant at 6 days postinfection. BVM displayed low-nanomolar IC 50 s against only some of the isolates (Table 4 ). In contrast, compound 7r was active across all the primary isolates, except the subtype A isolate 92UG031. This virus contains both CA-V230I and SP1-V7A polymorphisms (Fig. 3) . Our preliminary resistance data suggest that the combination of the V230I and V7A polymorphisms confers resistance to BVM analogs (data not shown). However, the frequency of both of these polymorphisms occurring together is very low, i.e., Ͻ1% of Ͼ30,000 viral sequences compiled in the Los Alamos HIV-1 sequence database (http://www.hiv.lanl.gov/content/index). Cytotoxicity was limited in PBMCs, with a BVM CC 50 of Ͼ10,000 nM and no toxicity observed for compound 7r at concentrations of up to 1,000 nM (data not shown). These data clearly demonstrate that relative to parental BVM, the C-28 alkyl amine derivatives of BVM display marked improvements in potency and breadth of activity.
DISCUSSION
In this study, we conducted an extensive medicinal chemistry campaign to develop novel maturation inhibitors that not only demonstrate increased potency against WT HIV-1 but also are active, in the low-nanomolar concentration range, against SP1-polymorphic HIV-1 isolates. The lack of antiviral activity against HIV-1 isolates with polymorphisms near the CA-SP1 cleavage site, particularly in SP1 residues 6 to 8, was a major reason for the discontinuation of BVM clinical development. In the present study, we synthesized a series of BVM analogs with C-28 modifications, with the top candidates potently inhibiting the processing of CA-SP1 and the viral replication of a representative polymorphic virus, the V7A variant. These compounds were also active against a multiclade panel of HIV-1 isolates in PBMCs. While several of the most potent compounds exhibited increased cytotoxicity in laboratory cell lines relative to that of BVM, cytotoxicity was not observed in PBMCs for concentrations of up to 1,000 nM. Recently, several other groups reported the synthesis and antiviral activity of BVM analogs. Most of these analogs have C-28 modifications and demonstrated slightly improved antiviral activity compared to that of BVM against prototypic clade B HIV-1 strains (34, 39, 40) . Interestingly, some of these BVM analogs reportedly inhibited both viral maturation and viral entry (32, 41) . In our study, the antiviral activity correlated well with CA-SP1 accumulation, and infection with a vesicular stomatitis virus glycoprotein G (VSV-G)-pseudotyped virus was potently inhibited by the BVM derivatives in single-cycle assays. In addition, the infectivity of virions bearing the HIV-1 Env glycoprotein was not affected by the inhibitors when they were present at the time of infection (data not shown). Thus, the compounds synthesized here act as maturation inhibitors, with no evidence of an entrybased inhibitory activity. In addition to C-28 modifications, it was reported that position C-3 can be derivatized without a loss of antiviral activity (39) . More recently, Dang et al. identified a C-28 BVM derivative that exhibited a 20-fold increased activity against a virus bearing the V7A polymorphism (32) . A series of macrocyclized betulinic acid derivatives was also reported; however, these compounds were not able to overcome the resistance conferred by the V7A polymorphism (40) . The most potent compounds in our study demonstrated IC 50 s against the V7A polymorph that were Ͼ50-fold lower than that of parental BVM. Thus, these compounds significantly contribute to the available information concerning the structure-activity relationships of HIV-1 maturation inhibitors.
The mechanism by which C-28 BVM derivatives potently and broadly inhibit HIV-1 replication relative to the action of the parental compound remains to be determined. The modifications may allow the C-28 side chain of the compound to interact more tightly with the putative Gag substrate. Although the binding site for BVM and its analogs has not been characterized structurally, several lines of evidence support the hypothesis that contacts are made between these compounds and two regions of Gag: the CA-SP1 boundary region and the major homology region (MHR) of CA. An early study demonstrated that BVM is specifically incorporated into immature but not mature particles (42) . Association of 3 H-labeled BVM with immature particles was reduced by resistance-conferring mutations at the CA-SP1 cleavage site (43) . Nguyen et al. demonstrated that a photoaffinity BVM analog interacted with residues around the CA-SP1 cleavage site and the CA MHR (44) . In a previous study (31) , we demonstrated that resistance to a structurally distinct maturation inhibitor, PF-46396, mapped not only to the vicinity of the CA-SP1 cleavage site (where BVM resistance mutations map) but also to the MHR. The MHR mutants were strongly compound dependent and could revert in culture by acquiring a mutation at residue 8 of SP1 (SP1-T8I). The ability of an SP1 mutation to rescue the replication defect con- Table 4 . Asterisks indicate amino acid sequence identity with WT NL4-3 (top line); gaps are indicated by hyphens. The QVT motif spanning SP1 residues 6 to 8 is in bold. ferred by an MHR substitution suggested functional cross talk between the MHR and SP1. It is interesting that residue 8 of SP1 falls within the so-called QVT motif (SP1 residues 6 to 8) previously shown to influence BVM activity (29) . The poor solubility of BVM and its analogs has hampered structural characterization of BVM binding, although a BVM derivative with improved solubility has been reported and shown by nuclear magnetic resonance (NMR) to bind a CA-SP1-NC peptide (45) . Adding to the challenging nature of defining the maturation inhibitor-binding site is the fact that the structure of the CA-SP1 boundary region of Gag is poorly defined. Although recent progress has been made in delineating the structure of the CA domain in the immature Gag lattice, the high level of flexibility of SP1 has thus far precluded an atomicresolution structure of SP1 in the immature particle (9) . Binding of maturation inhibitors to Gag may stabilize SP1 (46, 47) , thus potentially facilitating structural studies of this region. Mutations in SP1 may also limit the conformational flexibility of this peptide, providing another useful tool for structural studies.
The novel HIV-1 maturation inhibitors developed in this study provide insights into the structure-activity relationships of this class of compounds. Ongoing studies are aimed at further optimizing the potency and breadth of activity of these inhibitors.
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